These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 12767724)

  • 1. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
    de Gaetano G; Donati MB; Cerletti C
    Trends Pharmacol Sci; 2003 May; 24(5):245-52. PubMed ID: 12767724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
    Gaddi A; Cicero AF; Pedro EJ
    Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of thrombosis and vascular inflammation: importance of combined cyclooxygenase and 5-lipoxygenase inhibitors].
    Hatmi M; Samama MM; Elalamy I
    J Mal Vasc; 2006 Feb; 31(1):4-9. PubMed ID: 16609625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
    Celotti F; Durand T
    Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
    Alvaro-Gracia JM
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of anti-inflammatory treatment--new ways of thinking.
    Brune K
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
    Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
    Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.
    Fiorucci S; Distrutti E; Mencarelli A; Morelli A; Laufor SA; Cirino G; Wallace JL
    Br J Pharmacol; 2003 Aug; 139(7):1351-9. PubMed ID: 12890715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
    Bertolini A; Ottani A; Sandrini M
    Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
    Fiorucci S; Meli R; Bucci M; Cirino G
    Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
    Ye YN; Wu WK; Shin VY; Bruce IC; Wong BC; Cho CH
    Carcinogenesis; 2005 Apr; 26(4):827-34. PubMed ID: 15637091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
    Monsuez JJ
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors.
    Cusan C; Spalluto G; Prato M; Adams M; Bodensieck A; Bauer R; Tubaro A; Bernardi P; Da Ros T
    Farmaco; 2005 Apr; 60(4):327-32. PubMed ID: 15848208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs.
    Charlier C; Michaux C
    Eur J Med Chem; 2003; 38(7-8):645-59. PubMed ID: 12932896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.